30 closest matches · ranked by relevance
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants
Chronic Obstructive Pulmonary Disease
Primary: Number of Participants With Accurate Classification of Irreversible Airflow Obstruction — 10; 5 Participants
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change in Flow Mediated Dilation — 0.26; -1.5 percentage of flow mediated dilation
Chronic Obstructive Pulmonary Disease
Primary: Self-reported Intake of Fruit and Vegetables (Number of Portions Per Day); — 1.9; 6.1 Portions per day
Chronic Obstructive Pulmonary Disease
Primary: Death or Hospitalization, Whichever Occurs First — 34.2; 36.4 Composite events/100 person-years — p=0.52
Chronic Obstructive Pulmonary Disease
Primary: Time Spent in Physical Activity as Measured by Upright Time (Minutes Per Day) Monitored by ActivPal Monitor — 278; 269; 293; 285 minutes per day
COPD
Primary: Spirometry Measurement: Percentage of Predicted Forced Expiratory Volume in 1 Second (FEV1 %Pred) — 75.572; 100.837; 108.311; 111.849 percent of predicted FEV1 — p=<0.0001
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants Who Received COPD Prescription for Maintenance Treatment at Baseline — 735; 68; 554; 105 Participants
Chronic Obstructive Pulmonary Disease
Primary: Hospital Readmission — 1.12; 1.7 hospital readmissions
Chronic Obstructive Pulmonary Disease
Primary: Forced Expiratory Volume in the First Second (FEV1) — 54; 54 Percentage predicted — p=0.09
CHRONIC OBSTRUCTIVE PULMONARY DISEASE · ASTHMA · HEALTHY SUBJECTS
Primary: ANALYSIS OF LUNG DEPOSITION - Penetration Index — 0.8; 0.72; 0.69; 0.58 ratio
Chronic Obstructive Pulmonary Disease
Primary: Forced Expiratory Volume in One Second (FEV1), Peak Effect Within 0 - 24 Hours Post-dose — 1.71; 1.79; 1.72; 1.71 L
Pulmonary Disease, Chronic Obstructive
Primary: Flow-Mediated Dilation (FMD) — 3.1; 6.7; 4.7; 6.9 percentage of change in FMD — p=<0.05
Chronic Obstructive Pulmonary Disease · Acute Coronary Syndromes
Primary: COPD Diagnosis — 39 participants
Pulmonary Disease, Chronic Obstructive · Emphysema
Primary: 6 Minute Walk Distance — 458.2; 466.1 meters
Chronic Obstructive Pulmonary Disease
Primary: Participants Who Experienced Safety Concerns, Where Safety Concerns of Quercetin Supplementation is Indicated by Significant Change From Baseline Measures of Tests…
Chronic Obstructive Pulmonary Disease · COPD
Primary: Baseline Resting Cardiac Index (CI) — 2.4; 2.36 L/min/m^2 — p=0.85
Pulmonary Disease, Chronic Obstructive
Primary: Percentage of Participants Whose Post-albuterol Forced Expiratory Volume in One Second (FEV1) Was <80% Predicted Normal — 70; 30 percentage of participants
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Pre-dose FEV1 — 1.079; 1.009 Ratio — p=<.0001
Asthma · Pulmonary Disease, Chronic Obstructive
Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml
Chronic Obstructive Pulmonary Disease
Primary: Safety Profile of Oral Cyclosporin A Immunotherapy in Advanced Stage Chronic Obstructive Pulmonary Disease Patients- Nephrotoxicity - Measured by Serum Creatinine…
Pulmonary Disease, Chronic Obstructive
Primary: Age of the Chronic Obstructive Pulmonary Disease (COPD) Patients at the Time of COPD Diagnosis - US — 65.6; 64.4 Years
COPD · Emphysema · Emphysema or COPD
Primary: Pulmonary Microvascular Blood Volume, CV — 0.89; 0.88; 0.92; 0.91 CV — p=0.84
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants Who Prioritized Healthcare Topics — 90; 79; 23; 22 participants — p=.91
Pulmonary Disease, Chronic Obstructive · Smoking
Primary: Participation in Tobacco Cessation Treatment — 9; 29 Participants
Pulmonary Disease, Chronic Obstructive
Primary: Annualized Incidence Rate of Moderate or Severe Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) — 0.92; 0.95 AECOPD events/person-year — p=0.941
Pulmonary Disease, Chronic Obstructive
Primary: Percentage of Participants With COPD Who Rate the Use of the ELLIPTA Inhaler as Easy or Very Easy, Among Those Who Demonstrate Correct Use of the Inhaler at the End of…
COPD Exacerbation
Primary: Dyspnea Intensity — 8.0; 6.5; 7.75; 5 units on a scale
Pulmonary Disease, Chronic Obstructive · Lung Diseases · Respiratory Tract Diseases
Primary: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) — 1.61; 1.58; 1.62; 1.62 Liter
Chronic Obstructive Pulmonary Disease
Primary: Healthcare Utilization — 1080; 920 Participants — p=0.041